Clinical Trial Update: Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation [Phase 1, Phase 2]

View source ↗

Summary

An early-phase Phase 1/2a trial evaluating the combination of JAB-21822 and JAB-3312 in KRAS p.G12C-mutant advanced solid tumors, including non-small cell lung …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• JAB-21822
• JAB-3312

Snippet

Sponsor: Allist Pharmaceuticals, Inc. | Conditions: KRAS P.G12C, Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: RECRUITING